Generic Name:
Levetiracetam
Project Status:
Complete
Therapeutic Area:
Epilepsy
Manufacturer:
Pendopharm, a division of Pharmascience Inc.
Call for patient/clinician input open:
Brand Name:
pdp-levETIRAcetam
Project Line:
Reimbursement Review
Project Number:
SR0653-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For patients on levetiracetam that cannot intake solid oral tablets.
Submission Type:
Initial
Fee Schedule:
Schedule C
Indications:
Adjunctive therapy for: Adults management of patients with epilepsy who are not satisfactorily controlled by conventional therapyPediatrics partial onset seizures with or without secondary generalization in adolescents, children and infants from 1 month of age with epilepsy. myoclonic seizures in adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. primary generalized tonic-clonic seizures in adolescents from 12 years of age with Idiopathic Generalized Epilepsy.
Date NOC Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.